In addition, participants with metabolic disorders such as diabetes, hyperlipidemia, and hypercholesterolemia, as well as thyroid and hypothalamic disorders that may potentially affect LEAP2 regulation (72, 73), were excluded. This evidence concerns the gene LEAP2 and metabolic disease.